Top Biosimilars Companies

Skyquest Technology's expert advisors have carried out comprehensive research and identified these companies as industry leaders in the Biosimilars Market. This Analysis is based on comprehensive primary and secondary research on the corporate strategies, financial and operational performance, product portfolio, market share and brand analysis of all the leading Biosimilars industry players.

Biosimilars Market Competitive Landscape

The global biosimilars market has turned out to be a competitive and dynamic market.Major pharmaceutical and biotech firms are investing heavily in biosimilars to capitalize on market opportunities arising from the patent loss of blockbuster biologic medicines. Companies are concentrating on the development of biosimilars against high-revenue biologics, with high concentration on broadening the pipeline of biosimilars into fusion proteins, insulins, and monoclonal antibodies. For example, Sandoz (Novartis), being one of the leaders in the biosimilars market, is now concentrating on oncology and immunology biosimilars, including Zarxio (biosimilar of Neupogen) and Erelzi (biosimilar of Enbrel).

Top Players in Biosimilars Market

Biocon Biologics (India)
Celltrion (South Korea)
Sandoz (Switzerland)
Fresenius Kabi (Germany)
Teva Pharmaceuticals (Israel)
Amgen (USA)
Mylan (USA)
Coherus BioSciences (USA)
Alvotech (Iceland)
Polpharma Biologics (Poland)
Accord Healthcare (United Kingdom)
Formycon (Germany)
Pfizer (USA)

REPORT OVERVIEW BUY NOW

REQUEST FOR SAMPLE

Want to customize this report?

REQUEST FREE CUSTOMIZATION

FAQs

Biosimilars Market size was valued at USD 31.3 Billion in 2024 and is poised to grow from USD 35.71 Billion in 2025 to USD 102.59 Billion by 2033, growing at a CAGR of 14.1% during the forecast period (2026–2033).

Biosimilars market is highly competitive globally, with major pharmaceutical and biotech companies actively expanding their portfolios. The leading biosimilar companies invest in R&D, strategic alliances, and regulatory clearance to capture market share. Some of the notable contributors include Pfizer, Novartis (Sandoz), Amgen, Biocon Biologics, Samsung Bioepis, and Celltrion. These players use cutting-edge manufacturing, biosimilar interchangeability strategies, and competitive pricing to battle in the market. Some of the upcoming players such as Alvotech, Coherus BioSciences, and Polpharma Biologics are also emerging, making a difference through innovation and affordability. As biosimilar adoption increases, competition intensifies, fostering market growth and affordability of biologic treatments globally. 'Sandoz', 'Biocon Biologics', 'Celltrion Healthcare', 'Amgen Inc.', 'Pfizer Inc.', 'Samsung Biologics', 'Viatris', 'Teva Pharmaceutical Industries', 'Fresenius Kabi', 'Coherus BioSciences', 'Alvotech', 'STADA Arzneimittel AG', 'Reliance Life Sciences', 'Dr. Reddy’s Laboratories', 'Novartis AG', 'Formycon AG', 'Intas Pharmaceuticals', 'BIOCAD', 'mAbxience', 'Apotex Inc'

The growing prevalence of chronic diseases like cancer, diabetes, and autoimmune diseases is propelling the need for cheap biologic treatments. Biosimilars ensure cheaper substitutes to pricey biologics, enhancing patients' access to life-sustaining medicines. This surging demand for long-term therapeutic solutions continues to boost the biosimilar market.

Short-Term: Regulatory bodies such as the FDA and EMA are simplifying biosimilar approval procedures, resulting in more market entries. Faster approvals encourage competition, driving down costs and expanding accessibility. Healthcare providers and payers are more inclined to adopt biosimilars, causing a surge in market penetration and reshaping pricing strategies for both originator biologics and biosimilars.

North America continues to lead the global biosimilars market share, driven by a robust regulatory framework, significant R&D investments, and a surge in biosimilar approvals. In 2024, the U.S. Food and Drug Administration (FDA) approved 18 new biosimilars, reflecting the region's dynamic landscape for biosimilar therapies. The market is further bolstered by strategic shifts from major pharmacy benefit managers (PBMs) like UnitedHealth and CVS Health, which are increasingly favoring cost-effective biosimilars over branded biologics. This transition is expected to enhance patient access and drive substantial healthcare savings.

Top Biosimilars Companies

Biosimilars Market Competitive Landscape

Top Players in Biosimilars Market

FAQs

What is the global market size of Biosimilars Market?

Who are the key vendors in the Biosimilars Market?

What is the key driver of Biosimilars Market?

What is the key market trend for Biosimilars Market?

Which region accounted for the largest share in Biosimilars Market?

Request Free Customization